9 results about "Curative treatment" patented technology

Injectable photoelectrohydrogel for repairing retinal photoreceptor damage and its preparation method and application, photoelectroactive spirulina and conductive polymer poly(3,4-ethylenedioxythiophene) (PEDOT) hydrogel are physically cross-linked to construct an injectable material with photoelectric response characteristics, and the function of damaged photoreceptor cells in the retina is repaired in situ. Sp as a biologically active component not only gives the material photoelectric signal conversion capability, but also can achieve local antioxidant stress function, PEDOT-based hydrogel forms a three-dimensional scaffold by physically wrapping Sp, which not only ensures the activity of algal cells but also has excellent charge and ion conduction performance. The hydrogel can be injected into the retina to construct a biomimetic electrochemical signal transmission interface, rebuild the signal transduction of damaged photoreceptor cells, and realize the in situ repair of retinal signal pathways and the partial recovery of visual function. This technology provides a new strategy for the curative treatment of retinal diseases such as blinding eye diseases, and has the advantages of minimally invasive intervention, excellent biocompatibility and customizable treatment area.

In accordance with one or more embodiments herein, a system 100 is provided for healing RFA treatment of a treatment zone 300 comprising at least a portion of a cancer tumor by applying RF energy between an electrode disposed on a non-insulated ablation portion 124 of an RF probe 120 and another electrode 160. The system 100 comprises: a control device 110; an RF probe 120 comprising a non-insulating ablation portion 124; a temperature measurement device 130 arranged to measure the RF probe temperature and provide an estimate of the treatment zone temperature T to the control device 110 based thereon; a cooling device 140 provided to be controlled by the control device 110 to cool the RF probe 120; and RF generating means 150 controlled by the control means 110 to provide an amount of RF energy required to maintain the desired treatment zone temperature TD to the RF probe 120 based on the estimated treatment zone temperature T. The control device 110 is arranged to monitor the RF energy provided to the RF probe 120 by the RF generating device 150 and to turn off the RF generating device 150 at a point in time tP3 at which the output power of the RF generating device 150 is no longer substantially reduced.

Methods and compositions related to the treatment of autoimmune diseases using anti-CD45 antibody drug conjugates (ADCs) are disclosed. Described herein are methods and compositions for improving autohematopoietic stem cell transplantation (autoHSCT). Provided herein are methods and compositions for addressing known challenges in the field of autoHSCT, including antibodies and / or antibody drug conjugates (ADCs) that selectively target CD45 to purge autoimmune cells and enable autoHSCT as potential one-time healing treatment for patients with autoimmune diseases.

The present invention relates to the preventive or curative treatment of inflammatory diseases such as non-alcoholic fatty liver disease and inflammatory bowel diseases using Adlercreutzia bacteria.

The present invention relates to mixtures, or compositions comprising said mixtures, comprising at least one bacterial strain, preferably at least one probiotic bacterial strain or a derivative thereof, as well as to the use of said mixtures or compositions in methods for the preventive and / or curative treatment of an inflammatory ocular and / or periocular lesion, preferably in methods for the treatment of ocular diseases such as dry eyes, eyelid allergy, conjunctivitis, blepharitis, meibonite, dacryoliths, stye, inflammatory lesions of ocular adnexa and associated symptoms.

The invention relates to an injectable photoelectric hydrogel for repairing retina photosensitive function damage and a preparation method and application thereof, and the injectable photoelectric hydrogel is characterized in that photoelectric active spirulina and a conductive polymer poly (3, 4-ethylenedioxythiophene) (PEDOT) hydrogel are physically crosslinked to construct an injectable material with a photoelectric response characteristic, and functional repair of retina damaged photosensitive cells is realized in situ. Sp is used as a bioactive component, the material is endowed with photoelectric signal conversion capacity, the local anti-oxidative stress function can be achieved, PEDOT-based hydrogel physically coats Sp to form a three-dimensional support, algae cell activity is guaranteed, and excellent charge and ion conduction performance is achieved. The hydrogel can be injected into the retina to construct a bionic electrochemical signal transmission interface, signal transduction of damaged photoreceptor cells is reconstructed, and in-situ repair of a retina signal channel and partial recovery of a visual function are achieved. The technology provides a new strategy for curative treatment of blinding eye diseases such as retinopathy, and has the advantages of minimally invasive intervention, excellent biocompatibility, customizable treatment area and the like.

A method and composition for treating cancer through induction of tumor cell differentiation is disclosed. Cancer cells are converted into terminally differentiated, non-proliferating cell types using specific differentiation-inducing agents, including thyroid hormone analogs such as T2 and RT3. The approach avoids the cytotoxic effects and side effects associated with conventional chemotherapy while potentially providing curative treatment. Pharmaceutical compositions include topical formulations for skin cancer treatment and various delivery systems for systemic administration. In vitro screening methods for identifying differentiation-inducing agents are also provided.

Methods and compositions related to the treatment of autoimmune diseases using anti-CD45 antibody drug conjugates (ADCs) are disclosed. Described herein are methods and compositions for improving autologous hematopoietic stem cell transplantation (autoHSCT). Provided herein are methods and compositions for addressing known challenges in the field of autoHSCT, including antibodies and / or antibody drug conjugates (ADCs) that selectively target CD45 to clear autoimmune cells and enable autoHSCT as a potential one-time curative treatment for patients with autoimmune diseases.

This disclosure relates to a method for treating prostate-specific membrane antigen (PSMA)-positive oligometastatic prostate cancer (OMPC) that has progressed after curative treatment for the primary tumor, comprising a therapeutically effective amount of a PSMA-binding radioligand therapy (RLT) agent, preferably [ 177 Lu]Lu-PSMA-617(Lutetium( 177 The present disclosure relates to a method comprising administering (Lu) bipivotide tetraxetan. Furthermore, the present disclosure relates to radioligand therapy for early prostate cancer patients to control the progression of recurrent tumors to lethal metastatic disease while maintaining quality of life by delaying treatment with androgen deprivation therapy (ADT).